DNDI-6174
/ Eisai, DNDi
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 25, 2025
Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.
(PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
- "DNDI-6174 was stable under various conditions, including under tissue homogenization conditions, in all biomatrices investigated. This method was successfully applied in a translational study using a murine cutaneous leishmaniasis skin infection model to assess the target site pharmacokinetics of DNDI-6174, supporting its development as clinical candidate."
Journal • PK/PD data • Preclinical • Dermatology • Infectious Disease
December 13, 2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc.
(PubMed, Sci Transl Med)
- "No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis."
Journal • Preclinical • Infectious Disease
1 to 2
Of
2
Go to page
1